Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases.
OBJECTIVE
To assess the efficacy of 5% imiquimod cream on undifferentiated vulvar intraepithelial neoplasia (VIN), a disease caused by high-risk human papillomavirus.


METHODS
Prospective, uncontrolled study.


METHODS
University hospital vulvar clinic. Patients Twelve consecutive patients treated with 5% imiquimod cream for undifferentiated VIN between March 1, 1999, and May 31, 2001.


METHODS
Self-application of 5% imiquimod cream, initially 3 times a week, then adjusted according to tolerance, for up to 7 months according to clinical response.


METHODS
Therapeutic response, clinically assessed by successive photographs and histologically confirmed for complete responders, was scored as complete, partial (> or =50% decrease in lesion size), or failure. Tolerance was evaluated at each visit.


RESULTS
A total of 3, 4, and 5 patients achieved complete response, partial response (> or =75% reduction in lesion size for all such cases), and failure, respectively. Mean duration of treatment was 3.6 months (37.3 applications), 5.0 months (50.7 applications), and 3.4 months (25.2 applications) for complete responders, partial responders, and failures, respectively. Follow-up after treatment was 5 to 18, 14 to 32, and 2 to 28 months, respectively, with 1 partial responder lost to long-term follow-up. No patient developed invasive carcinoma. All but 2 patients experienced vulvar discomfort, resulting in treatment withdrawal for 3. Two patients had flulike symptoms.


CONCLUSIONS
Imiquimod cream could be a therapeutic option for undifferentiated VIN. Although poorly tolerated, this self-applied treatment could spare patients, either totally or partially, the classic painful and sometimes mutilating treatments of VIN. Controlled, randomized studies are needed to evaluate its efficacy and tolerance.
Wendling
Jeanne
J
Service de Dermatologie Générale et Oncologique and Service d'Anatomopathologie, Hôpital Ambroise-Paré, Assistance Publique des Hôpitaux de Paris, Université Versailles Saint-Quentin en Yvelines, 92104 Boulogne, France.
Saiag
Philippe
P
Berville-Levy
Sophie
S
Bourgault-Villada
Isabelle
I
Clerici
Thierry
T
Moyal-Barracco
Micheline
M
D000279:Administration, Cutaneous; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008875:Middle Aged; D027383:Papillomaviridae; D011230:Precancerous Conditions / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D011446:Prospective Studies; D016896:Treatment Outcome; D014846:Vulvar Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod